This consent form for the CanSeq study included permission to perform genetic tests on tissue specimens that had already been collected and stored as part of clinical care or other research studies the person participated in.

The Institutional and Professional Impact of Genomic Sequencing in Cancer Care examined the impact of the use of whole-exome sequencing (WES) on physicians and institutional systems at the Dana-Farber Cancer Institute (DFCI). This consent form is for clinically active oncologists involved in the care of cancer patients and members of the Cancer Genomics Evaluation Committee (CGEC), which was established to guide the incorporation of WES into cancer care.

This research consent and authorization form for enrollment in the NextGen trial by male partners of female Kaiser Permanente patients who requested carrier testing for inherited condition or disease before getting pregnant or during pregnancy.

This research consent and authorization form for enrollment in the NextGen trial by female Kaiser Permanente patients who requested carrier testing for inherited condition or disease before getting pregnant or during pregnancy.

This informed consent document for parents and minors in the Genomic Diagnosis in Children with Developmental Delay study includes standard consent language plus consent to storage of specimens for future use, to be contacted about new research studies, and to share genetic and health information in the dbGaP database.

This consent form for the Personalized Oncology Through High-throughput Sequencing: MI-ONCOSEQ (Michigan Oncology Sequencing Center) study includes authorization to create cell lines from participant tumor tissue and to store clinical information and samples for use in ongoing research.

This consent/ assent form for adults, adolescents, and parents of minors in the Personalized Medicine Based on Molecular Profiling of Patients with Cancer study includes consent to the use of tumor cells to create cell lines, consent to additional analysis of the sequencing data for research purposes, and "right not to know" provisions for results that may have significance for biological family members and results that may have potential medical impact.

This parental consent form from the NCGENES: A Next-Generation Sequencing Platform for Genetic Diagnosis study is designed for the minor relatives of NCGENES study participants that received a genetic test result containing a variant of uncertain significance (VUS). This parental consent is for the minor relative to be tested for the VUS previously identified in the NCGENES study participant, not enrollment in the full NCGENES study.

This assent form from the NCGENES: A Next-Generation Sequencing Platform for Genetic Diagnosis study is designed for the 7 - 14 year old relatives of NCGENES study participants with a genetic test result containing a variant of uncertain significance (VUS). This assent is for the relative to be tested for the VUS previously identified in the NCGENES study participant, not enrollment in the full NCGENES study.

This assent form from the NCGENES: A Next-Generation Sequencing Platform for Genetic Diagnosis study is designed for the adolescent (aged 15-17) relatives of NCGENES study participants with a genetic test result containing a variant of uncertain significance (VUS). This assent is for the relative to be tested for the VUS previously identified in the NCGENES study participant, not enrollment in the full NCGENES study.